Regression of extensive pulmonary metastases in mice by adoptive transfer of antigen-specific CD8(+) CTL reactive against tumor cells expressing a naturally occurring rejection epitope - PubMed (original) (raw)
. 2001 Oct 15;167(8):4286-92.
doi: 10.4049/jimmunol.167.8.4286.
Affiliations
- PMID: 11591751
- DOI: 10.4049/jimmunol.167.8.4286
Free article
Regression of extensive pulmonary metastases in mice by adoptive transfer of antigen-specific CD8(+) CTL reactive against tumor cells expressing a naturally occurring rejection epitope
M H Ryan et al. J Immunol. 2001.
Free article
Abstract
In this study, we developed a mouse model of adoptive immunotherapy reflecting immune recognition of syngeneic tumor cells naturally expressing an endogenous rejection Ag. Specifically, in a pulmonary metastases model, we examined the potency and maintenance of an antitumor CD8(+) CTL response in vivo, as well as its effectiveness against an "extensive" tumor burden. The approach taken was to first generate tumor-specific CTL from mice challenged with the CMS4 sarcoma coadministered with anti-CTLA4 mAb, which has been shown to facilitate the induction of Ag-specific T cell responses in vivo. An H-2L(d)-restricted nonamer peptide, derived from an endogenous murine leukemia provirus was identified as a CMS4-reactive CTL epitope based upon the following: CTL cross-recognition of another syngeneic tumor cell line (CT26 colon carcinoma) previously characterized to express that gene product; sensitization of Ag-negative lymphoblasts or P815 targets with the peptide; and by cold target inhibition assays. In vivo, the adoptive transfer of CMS4-reactive CTL (> or =1 x 10(6)) resulted in nearly the complete regression of 3-day established lung metastases. Furthermore, mice that rejected CMS4 following a single adoptive transfer of CTL displayed antitumor activity to a rechallenge 45 days later, not only in the lung, but also at a s.c. distal site. Lastly, the adoptive transfer of CTL to mice harboring extensive pulmonary metastases (> 150 nodules) led to a substantial reduction in tumor burden. Overall, these data suggest that the adoptive transfer of tumor-specific CTL may have therapeutic potential for malignancies that proliferate in or metastasize to the lung.
Similar articles
- The Fas/Fas ligand pathway is important for optimal tumor regression in a mouse model of CTL adoptive immunotherapy of experimental CMS4 lung metastases.
Caldwell SA, Ryan MH, McDuffie E, Abrams SI. Caldwell SA, et al. J Immunol. 2003 Sep 1;171(5):2402-12. doi: 10.4049/jimmunol.171.5.2402. J Immunol. 2003. PMID: 12928387 - Characterization of CD8+ cytotoxic T lymphocyte/tumor cell interactions reflecting recognition of an endogenously expressed murine wild-type p53 determinant.
Hilburger Ryan M, Abrams SI. Hilburger Ryan M, et al. Cancer Immunol Immunother. 2001 Jan;49(11):603-12. doi: 10.1007/s002620000156. Cancer Immunol Immunother. 2001. PMID: 11225991 Free PMC article. - Tumor-specific CTL kill murine renal cancer cells using both perforin and Fas ligand-mediated lysis in vitro, but cause tumor regression in vivo in the absence of perforin.
Seki N, Brooks AD, Carter CR, Back TC, Parsoneault EM, Smyth MJ, Wiltrout RH, Sayers TJ. Seki N, et al. J Immunol. 2002 Apr 1;168(7):3484-92. doi: 10.4049/jimmunol.168.7.3484. J Immunol. 2002. PMID: 11907109 - Induction of CTL responses by simultaneous administration of liposomal peptide vaccine with anti-CD40 and anti-CTLA-4 mAb.
Ito D, Ogasawara K, Iwabuchi K, Inuyama Y, Onoé K. Ito D, et al. J Immunol. 2000 Feb 1;164(3):1230-5. doi: 10.4049/jimmunol.164.3.1230. J Immunol. 2000. PMID: 10640735 - Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy.
Durgeau A, Virk Y, Corgnac S, Mami-Chouaib F. Durgeau A, et al. Front Immunol. 2018 Jan 22;9:14. doi: 10.3389/fimmu.2018.00014. eCollection 2018. Front Immunol. 2018. PMID: 29403496 Free PMC article. Review.
Cited by
- G6PD functions as a metabolic checkpoint to regulate granzyme B expression in tumor-specific cytotoxic T lymphocytes.
Lu C, Yang D, Klement JD, Colson YL, Oberlies NH, Pearce CJ, Colby AH, Grinstaff MW, Ding HF, Shi H, Liu K. Lu C, et al. J Immunother Cancer. 2022 Jan;10(1):e003543. doi: 10.1136/jitc-2021-003543. J Immunother Cancer. 2022. PMID: 35017152 Free PMC article. - Type I interferon suppresses tumor growth through activating the STAT3-granzyme B pathway in tumor-infiltrating cytotoxic T lymphocytes.
Lu C, Klement JD, Ibrahim ML, Xiao W, Redd PS, Nayak-Kapoor A, Zhou G, Liu K. Lu C, et al. J Immunother Cancer. 2019 Jun 22;7(1):157. doi: 10.1186/s40425-019-0635-8. J Immunother Cancer. 2019. PMID: 31228946 Free PMC article. - PD-L1 restrains PD-1+Nrp1lo Treg cells to suppress inflammation-driven colorectal tumorigenesis.
Poschel DB, Klement JD, Merting AD, Lu C, Zhao Y, Yang D, Xiao W, Zhu H, Rajeshwari P, Toscano M, Jones K, Barrett A, Bollag RJ, Fallon PG, Shi H, Liu K. Poschel DB, et al. Cell Rep. 2024 Oct 22;43(10):114819. doi: 10.1016/j.celrep.2024.114819. Epub 2024 Oct 3. Cell Rep. 2024. PMID: 39368087 Free PMC article. - Autologous cellular vaccine overcomes cancer immunoediting in a mouse model of myeloma.
Mazzocco M, Martini M, Rosato A, Stefani E, Matucci A, Dalla Santa S, De Sanctis F, Ugel S, Sandri S, Ferrarini G, Cestari T, Ferrari S, Zanovello P, Bronte V, Sartoris S. Mazzocco M, et al. Immunology. 2015 Sep;146(1):33-49. doi: 10.1111/imm.12477. Epub 2015 Jun 15. Immunology. 2015. PMID: 25959091 Free PMC article. - Immunotherapeutic strategies for high-risk bladder cancer.
Sharma P, Old LJ, Allison JP. Sharma P, et al. Semin Oncol. 2007 Apr;34(2):165-72. doi: 10.1053/j.seminoncol.2006.12.004. Semin Oncol. 2007. PMID: 17382800 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials